A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06660173 on ClinicalTrials.gov · last registry update 2025-11-25
An unusually large phase 2: 409 participants, more than double the 114 typical for the stage. The sponsor logged completion for 6 October 2025. Primary outcome, as filed: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c). maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 409
- Started
- 2024-11-07
- Primary completion
- 2025-10-06 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)
Conditions studied
Type 2 Diabetes Mellitus (T2DM)
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.